Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation.

In recent years, mesenchymal stem cells (MSCs) have been shown to inhibit T-lymphocyte proliferation induced by alloantigens or mitogens. However, no substantial information is available regarding their effect on natural killer (NK) cells. Here we show that MSCs sharply inhibit IL-2-induced proliferation of resting NK cells, whereas they only partially affect the proliferation of activated NK cells. In addition, we show that IL-2-activated NK cells (but not freshly isolated NK cells) efficiently lyse autologous and allogeneic MSCs. The activating NK receptors NKp30, NKG2D, and DNAM-1 represented the major receptors responsible for the induction of NK-mediated cytotoxicity against MSCs. Accordingly, MSCs expressed the known ligands for these activating NK receptors-ULBPs, PVR, and Nectin-2. Moreover, NK-mediated lysis was inhibited when IFN-gamma-exposed MSCs were used as target cells as a consequence of the up-regulation of HLA class I molecules at the MSC surface. The interaction between NK cells and MSCs resulted not only in the lysis of MSCs but also in cytokine production by NK cells. These results should be taken into account when evaluating the possible use of MSCs in novel therapeutic strategies designed to improve engraftment or to suppress graft-versus-host disease (GVHD) in bone marrow transplantation.

[1]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.

[2]  C. Biron.  Activation and function of natural killer cell responses during viral infections. , 1997, Current opinion in immunology.

[3]  D J Prockop,et al.  Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S. Gerson,et al.  Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. , 2000, Journal of hematotherapy & stem cell research.

[5]  P. Rameshwar,et al.  Veto-Like Activity of Mesenchymal Stem Cells: Functional Discrimination Between Cellular Responses to Alloantigens and Recall Antigens1 , 2003, The Journal of Immunology.

[6]  E. Romeo,et al.  CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell‐mediated cytotoxicity , 2003, European journal of immunology.

[7]  E. Romeo,et al.  Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells , 2004, European journal of immunology.

[8]  Elizabeth Simpson,et al.  Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. , 2003, Blood.

[9]  R. Biassoni,et al.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. , 2001, Annual review of immunology.

[10]  O. Ringdén,et al.  Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells , 2003, Transplantation.

[11]  M. Pittenger,et al.  Human mesenchymal stem cells modulate allogeneic immune cell responses. , 2005, Blood.

[12]  A Steinle,et al.  Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. , 1999, Science.

[13]  Paul D. Kessler,et al.  Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart , 2002, Circulation.

[14]  R. Biassoni,et al.  Identification of NKp80, a novel triggering molecule expressed by human NK cells , 2001, European journal of immunology.

[15]  O. Ringdén,et al.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.

[16]  L. Notarangelo,et al.  NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. , 2001, The Journal of experimental medicine.

[17]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.

[18]  R. Armitage,et al.  ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. , 2001, Immunity.

[19]  L. Moretta,et al.  Erratum: The natural killer cell-mediated killing of autologous dendritic cells in confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors (European Journal of Immunology (2003) vol. 33 (6) (1657-1666)) , 2003 .

[20]  G. Trinchieri,et al.  Biology of Natural Killer Cells , 1989, Advances in Immunology.

[21]  R. Deans,et al.  Mesenchymal stem cells: biology and potential clinical uses. , 2000, Experimental hematology.

[22]  E. Guinan,et al.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.

[23]  L. Moretta,et al.  Unravelling natural killer cell function: triggering and inhibitory human NK receptors , 2004, The EMBO journal.

[24]  F. Djouad,et al.  Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. , 2003, Blood.

[25]  T. Mcclanahan,et al.  DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. , 1996, Immunity.

[26]  D. Mevorach,et al.  Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. , 2005, Blood.

[27]  S. Ferrone,et al.  Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. , 2002, Cancer research.

[28]  S. Haynesworth,et al.  Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation , 2004, Bone Marrow Transplantation.

[29]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[30]  J. Mosca,et al.  Characterization and functionality of cell surface molecules on human mesenchymal stem cells. , 2003, Journal of biomedical science.

[31]  R. Biassoni,et al.  Identification and Molecular Characterization of Nkp30, a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells , 1999, The Journal of experimental medicine.

[32]  J. Luhm,et al.  NK cells: a lesson from mismatched hematopoietic transplantation. , 2003, Trends in immunology.

[33]  M. Caligiuri,et al.  NK cell and DC interactions. , 2004, Trends in immunology.

[34]  L. Moretta,et al.  The natural killer cell‐mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig‐like receptors , 2003, European journal of immunology.

[35]  L. Moretta,et al.  Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.

[36]  D. Goodlett,et al.  HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. , 1998, Journal of immunology.

[37]  A. Moretta.  Natural killer cells and dendritic cells: rendezvous in abused tissues , 2002, Nature Reviews Immunology.

[38]  O. Ringdén,et al.  Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  G. Trinchieri,et al.  Molecular cloning and biological characterization of NK cell activation‐inducing ligand, a counterstructure for CD48 , 1999, European journal of immunology.

[40]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[41]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[42]  A. Tichelli,et al.  Use of natural killer cells in hematopoetic stem cell transplantation , 2005, Bone Marrow Transplantation.

[43]  M. Pittenger,et al.  Mesenchymal stem cells and their potential as cardiac therapeutics. , 2004, Circulation research.

[44]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[45]  Kevin McIntosh,et al.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. , 2002, Experimental hematology.

[46]  Jun Wu,et al.  An activating immunoreceptor complex formed by NKG2D and DAP10. , 1999, Science.

[47]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[48]  R. Biassoni,et al.  Receptors for HLA class-I molecules in human natural killer cells. , 1996, Annual review of immunology.

[49]  J. Mosca,et al.  T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. , 2005, Journal of biomedical science.

[50]  A. Caplan,et al.  Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5‐azacytidine , 1995, Muscle & nerve.

[51]  Andrea Bacigalupo,et al.  Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[52]  R. Biassoni,et al.  2B4 functions as a co‐receptor in human NK cell activation , 2000, European journal of immunology.

[53]  S. Gerson,et al.  Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.